The high price of anticancer drugs: origins, implications, barriers, solutions
The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Innovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359
Projections of the cost of cancer care in the United States: 2010–2020
Mariotto, A. B., Robin Yabroff, K., Shao, Y., Feuer, E. J., & Brown, M. L. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq495 · Cited by 2,657
Pochon, S. (2005) · American Journal of Cancer · doi:10.2165/00024669-200504040-00008 · Cited by 1,424
Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer
Ramsey, S. D., Bansal, A., Fedorenko, C. R., Blough, D. K., Overstreet, K. A., Shankaran, V., & Newcomb, P. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.6620 · Cited by 912
Bower, H., Björkholm, M., Dickman, P. W., Höglund, M., Lambert, P. C., & Andersson, T. M.-L. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.2866 · Cited by 904
Cited by
Advances in Oral Drug Delivery
Alqahtani, M. S., Kazi, M., Alsenaidy, M. A., & Ahmad, M. Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.618411 · Cited by 876
Prasad, V., & Mailankody, S. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.3601 · Cited by 503
Self-citationPriorities for cancer research in low- and middle-income countries: a global perspective
Pramesh, C. S., Badwe, R. A., Bhoo-Pathy, N., Booth, C. M., Chinnaswamy, G., Dare, A. J., de Andrade, V. P., Hunter, D. J., Gopal, S., Gospodarowicz, M., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01738-x · Cited by 434
How much does it cost to research and develop a new drug? A systematic review and assessment
Schlander, M., Hernandez-Villafuerte, K., Cheng, C.-Y., Mestre-Ferrandiz, J., & Baumann, M. (2021) · PharmacoEconomics · doi:10.1007/s40273-021-01065-y · Cited by 360
“[22] reported median costs as the main results.”
BackgroundEndophytic Fungi—Alternative Sources of Cytotoxic Compounds: A Review
Uzma, F., Mohan, C. D., Hashem, A., Konappa, N. M., Rangappa, S., Kamath, P. V., Singh, B. P., Mudili, V., Gupta, V. K., Siddaiah, C. N., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00309 · Cited by 293
Aguiar, P. N., Haaland, B., Park, W., San Tan, P., del Giglio, A., & de Lima Lopes, G. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.1395 · Cited by 124
“As the cost of new anticancer drugs continues to increase at a double-digit percentage every year, the challenge of addressing extreme health care costs has become increasingly immediate.(26,27) For the presentstudy,wechose representativehigh-incomeandhigher-”
BackgroundMullane, K., & Williams, M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.026 · Cited by 98
Using single‐cell multiple omics approaches to resolve tumor heterogeneity
Ortega, M. A., Poirion, O., Zhu, X., Huang, S., Wolfgruber, T. K., Sebra, R., & Garmire, L. X. (2017) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0177-y · Cited by 81
Mullane, K., & Williams, M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.027 · Cited by 32
Benjamin, D. J., Haslam, A., & Prasad, V. (2024) · Cancer Medicine · doi:10.1002/cam4.7049 · Cited by 30
Self-citationRepurposing drugs targeting metabolic diseases for cancer therapeutics
Pillai U, J., Ray, A., Maan, M., & Dutta, M. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103684 · Cited by 31
Exploiting convergent phenotypes to derive a pan-cancer cisplatin response gene expression signature
Scarborough, J. A., Eschrich, S. A., Torres-Roca, J., Dhawan, A., & Scott, J. G. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00375-y · Cited by 14
“These therapies have produced some inspiring successes, extending the lives of patients with targetable mutations by months to years 1 – 3 .”
Metadata
- Authors
- Prasad, V., De Jesús, K., & Mailankody, S.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2017-03-14
- Volume
- 14
- Issue
- 6
- Pages
- 381-390
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W2600333833
- Cited by
- 442
- References
- 60
- FWCI
- 21.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.